Cancer Genetics (CGIX) Issues Earnings Results, Beats Expectations By $0.02 EPS

Cancer Genetics (NASDAQ:CGIX) issued its quarterly earnings data on Tuesday. The medical research company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02, MarketWatch Earnings reports. Cancer Genetics had a negative return on equity of 121.10% and a negative net margin of 87.08%. The company had revenue of $6.80 million for the quarter.

Shares of NASDAQ CGIX opened at $0.24 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.46 and a quick ratio of 0.46. The stock has a market capitalization of $6.87 million, a price-to-earnings ratio of -0.31 and a beta of 1.17. Cancer Genetics has a fifty-two week low of $0.20 and a fifty-two week high of $1.30.

In other Cancer Genetics news, CFO Michael Glenn Miles purchased 150,000 shares of the stock in a transaction on Thursday, January 31st. The stock was acquired at an average price of $0.23 per share, with a total value of $34,500.00. Following the completion of the acquisition, the chief financial officer now owns 150,000 shares in the company, valued at $34,500. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO John A. Roberts purchased 185,436 shares of the stock in a transaction on Thursday, January 31st. The stock was acquired at an average cost of $0.23 per share, with a total value of $42,650.28. Following the acquisition, the chief executive officer now owns 297,636 shares of the company’s stock, valued at approximately $68,456.28. The disclosure for this purchase can be found here. In the last three months, insiders acquired 1,335,436 shares of company stock valued at $307,150. Corporate insiders own 21.30% of the company’s stock.

An institutional investor recently raised its position in Cancer Genetics stock. Geode Capital Management LLC grew its holdings in Cancer Genetics Inc (NASDAQ:CGIX) by 106.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 221,803 shares of the medical research company’s stock after acquiring an additional 114,448 shares during the quarter. Geode Capital Management LLC owned 0.80% of Cancer Genetics worth $53,000 at the end of the most recent reporting period. 9.00% of the stock is currently owned by hedge funds and other institutional investors.

Separately, ValuEngine raised Cancer Genetics from a “hold” rating to a “buy” rating in a research report on Monday, February 4th.

ILLEGAL ACTIVITY WARNING: “Cancer Genetics (CGIX) Issues Earnings Results, Beats Expectations By $0.02 EPS” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at

Cancer Genetics Company Profile

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Recommended Story: Are analyst ratings accurate?

Earnings History for Cancer Genetics (NASDAQ:CGIX)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.